symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
RANI,2.06,0.333999,48576,109260746,0,1.85-8.99,-0.14,"Rani Therapeutics Holdings, Inc.",USD,0001856725,US7530181004,753018100,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.ranitherapeutics.com,"Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.",Mr. Talat  Imran,Healthcare,US,163,408 457 3700,2051 Ringwood Avenue,San Jose,CA,95131,,0,https://financialmodelingprep.com/image-stock/RANI.png,2021-07-30,False,False,True,False,False
